<DOC>
	<DOCNO>NCT02466516</DOCNO>
	<brief_summary>This study evaluate safety tolerability GS-4997 alone combination Simtuzumab ( SIM ) adult Nonalcoholic Steatohepatitis ( NASH ) Fibrosis Stages F2-F3 . Participants randomize 2:2:1:1:1 ratio 1 5 study treatment arm .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy GS-4997 Alone Combination With Simtuzumab ( SIM ) Adults With Nonalcoholic Steatohepatitis ( NASH ) Fibrosis Stages F2-F3</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Key Males nonpregnant , nonlactating female Evidence NASH fibrosis biopsy Key Cirrhosis liver ( e.g . Brunt/Kleiner score F4 ) Other cause liver disease include viral hepatitis alcoholic liver disease Any history decompensated liver disease , include ascites , hepatic encephalopathy variceal bleed History liver transplantation Alcohol consumption great 21 oz/week male 14 oz/week female ( 1 oz/30 mL alcohol present 1 12 oz/360 mL beer , 1 4 oz/120 mL glass wine , 1 oz/30 mL measure 40 % proof alcohol ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GS-4997</keyword>
	<keyword>Non-alcoholic fatty liver disease ( NAFLD )</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Simtuzumab</keyword>
</DOC>